Pfizer makes strategic investment in antibacterial and antifungal R&D to get new products to market

New medicines and vaccines are needed urgently to target priority pathogens. However, it can be risky to invest in developing antibacterial and antifungal products.

Explore further

Get in touch

Back to top |